TickerGuard
Buy Day today: Neutral (54) Mixed market breadth · no major macro event
CGEN

Compugen

Healthcare · Biotechnology

2.40$ +0.9% vs. previous close Closing price · As of: Sep 29, 2026

Ownership

Ownership Structure

Who owns Compugen (CGEN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 97.8% of the shares are freely tradable; institutional investors hold 15.3%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 15.3%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 2.1%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 97.8%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 2.5%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 95Mio.

Largest Shareholders

Funds

Funds CGEN
Name Stake (%) Shares Change (%) Date
Nomura Healthcare Fund Class I 1.08 1,020,000 +0.0 07/31/2026
ARK Israel Innovative Technology ETF 0.94 887,867 +0.0 08/31/2026
State Street® SPDR® Ptf Dev Wld exUS ETF 0.37 351,876 +0.3 08/31/2026
Taylor Frigon Core Growth 0.26 242,969 +0.0 05/31/2026
Avantis International Small Cap Val ETF 0.09 87,369 +0.0 08/31/2026
DFA International Core Equity 2 I 0.08 71,228 +2.5 07/31/2026
State Street® SPDR® S&P® Intl Sm Cp ETF 0.07 64,038 +0.0 08/31/2026
Fidelity Nasdaq Composite Index 0.06 56,738 +0.0 07/31/2026
Invesco NASDAQ Future Gen 200 ETF 0.04 42,470 -0.1 08/31/2026
Avantis Global Small Cap Val ETF USD Acc 0.04 34,882 +0.0 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?